# Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

Study · id `cardio:ct-nct05918861` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05918861](<https://clinicaltrials.gov/study/NCT05918861>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05918861

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2000 participants.

## Technical summary

Registry record NCT05918861. Randomized; quadruple masking; primary purpose treatment. Start 2023-10-03 (actual); primary completion 2027-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 2000 participants (planned count; ClinicalTrials.gov record NCT05918861, source copy `cardio:ctgov-nct05918861-2026-06-22`, retrieved 2026-10-31)
- Started: 2023-10-03 (actual) (ClinicalTrials.gov record NCT05918861, source copy `cardio:ctgov-nct05918861-2026-06-22`, retrieved 2026-10-31)
- Primary completion: 2027-08 (anticipated) (ClinicalTrials.gov record NCT05918861, source copy `cardio:ctgov-nct05918861-2026-06-22`, retrieved 2026-10-31)
- Completion: 2027-08 (anticipated) (ClinicalTrials.gov record NCT05918861, source copy `cardio:ctgov-nct05918861-2026-06-22`, retrieved 2026-10-31)
- Countries: United States; Canada; Puerto Rico (ClinicalTrials.gov record NCT05918861, source copy `cardio:ctgov-nct05918861-2026-06-22`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05918861-2026-06-22`, retrieved 2026-10-31)

## The registry's words

- Brief title: Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
- Acronym: dal-GenE-2
- Condition: Acute Coronary Syndrome
- Intervention (Drug): Dalcetrapib
- Intervention (Drug): Placebo
- Lead sponsor: DalCor Pharmaceuticals
- Lead sponsor class: INDUSTRY
- Collaborator: The Montreal Health Innovations Coordinating Center (MHICC)
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry lists this organization as a collaborator: The Montreal Health Innovations Coordinating Center (MHICC) (`cardio:org-the-montreal-health-innovations-coordinating-center-mhicc`)

## Provenance

Content hash: a75d8b37d608573cd6c0265a72c0e9ac554bb0a79f6de611e85569cd418df3b0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
